Yongsu Zhen 



Chinese Society of Engineering


Anti-cancer Drugs Branch of Chinese Anti-Cancer Association

Professor Yongsu Zhen is a microbial pharmacologist, biotechnical pharmacologist and tumor pharmacologist. He’s academician of the Chinese Academy of Engineering from Kaiping, Guangdong Province, graduating from the School of Medicine of Sun Yat-sen University in 1954. He’s now a researcher, professor and doctoral supervisor in the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences. In 1979, he went to John Hopkins University as visiting scholar to conduct immunity and pharmacology researches in the Department of Pharmacology and Experimental Therapeutics, School of Medicine. In 1981 and 1986, he conducted experimental tumor and biochemical pharmacological researches in the School of Medicine in Indiana University as visiting professor. He used to serve as a member of National New Drug Research and Development Expert Committee, member of Biotechnology Expert Consultation Committee of the Ministry of Health, executive member of Chinese Pharmacopoeia Commission, Chairman of Anti-cancer Drug Professional Board of Chinese Anti-cancer Association, Chairman of Tumor Pharmacology Professional Board of Chinese Pharmacological Society, Chairman of Antibody Engineering Professional Board of China Medicinal Biotechnology Association, Director of Chinese Society of Biotechnology and of Chinese Medical Association; he’s also Head of the Editorial Board of Modern Biotechnological Pharmaceutics Series, Editor-in-chief of Biological Drug Research and Application Series, Editor-in-chief of The Medical Encyclopedia of China (Pharmacy), Head of the Editorial Board of Chinese Journal of Antibiotics, and Deputy Editor-in-chief of Acta Academiae Medicinae Sinicae, Chinese Medical Sciences Journal (English Version) and Chinese Pharmaceutical Journal.

He conducted research and development of antitumor antibiotics (including bleomycin, mithramycin, pingyangmycin, boanmycin and lidamycin); pingyangmycin whose development was hosted by him has been in clinical application for more than three decades, used to treat head and neck squamous cell carcinoma. Pingyangmycin was included in Chinese Pharmacopoeia and listed among National Essential Drugs; boanmycin is a clinical drug to treat tumors. He’s also engaged in the research of screening methods of anti-tumor drugs, establishing “spermatogonium method” to be applied to drug screening and finding new-type antitumor antibiotics C-1027 (lidamycin) and building the screening method making nucleoside transport the target spot to search for and develop new-type anti-tumor biochemical modulation drugs. He also conducted researches of antitumor targeted drugs and immunotherapeutic drugs and probed into the orientation to high efficiency, multi-target and small molecule of ADC and LDC.

Among the postgraduates under his supervision, there’re 64 obtaining Doctor’s Degree and 17 Master’s Degree. He had more than 300 papers published, edited or co-edited five monographs, namely, Antibody Engineering Drugs, Biological Activity and Therapeutic Potency of Tea (English Version), Antitumor Drug Research and Development, Antibody Drug Research and Application and Healthcare Functions of Tea. He used to win one second place in State Invention Award, one National Science Conference Achievement Award and two first places in ministerial science and technology progress awards. And he was authorized more than 20 invention patents. In 1986, he was awarded the title “Middle-aged and Young Expert of Outstanding Contribution” by the State Ministry of Personnel; in Nov. 1997, he was admitted as academician of the Chinese Academy of Engineering; in 2001, he was granted Ho Leung Ho Lee Foundation Award for Scientific and Technological Progress.